Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial

Gino A. Vena, Nicoletta Cassano, Delia Colombo, Elena Peruzzi, Paolo Pigatto

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Background: Treatment of severe recalcitrant chronic idiopathic urticaria (CIU) is difficult. Objective: To assess the efficacy and safety of oral cyclosporin A (CsA) in CIU. Methods: The response to CsA was evaluated in 99 CIU patients with a double-blind, randomized, three-armed study: 16-week CsA, 8-week CsA +8-week placebo, and 16-week placebo. All patients received cetirizine throughout the study period and were followed-up after 8 weeks. Results: Fewer therapeutic failures occurred with 16-week CsA (n = 3) than with placebo (n = 11) and 8-week CsA (n = 8). After 8 and 16 weeks, symptom scores significantly improved in both CsA groups over with placebo. Two patients discontinued because of hypertension. Limitations: During the study period, CsA was not administered at a constant dose; from day 28 the daily dose was 3 mg/kg, which is likely to be less effective and better tolerated than higher dosages. Conclusion: CsA in addition to background therapy with cetirizine may be useful in the treatment of CIU.

Original languageEnglish
Pages (from-to)705-709
Number of pages5
JournalJournal of the American Academy of Dermatology
Volume55
Issue number4
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Urticaria
Cyclosporine
Randomized Controlled Trials
Placebos
Cetirizine
Therapeutics
Hypertension
Safety

ASJC Scopus subject areas

  • Dermatology

Cite this

Cyclosporine in chronic idiopathic urticaria : A double-blind, randomized, placebo-controlled trial. / Vena, Gino A.; Cassano, Nicoletta; Colombo, Delia; Peruzzi, Elena; Pigatto, Paolo.

In: Journal of the American Academy of Dermatology, Vol. 55, No. 4, 10.2006, p. 705-709.

Research output: Contribution to journalArticle

Vena, Gino A. ; Cassano, Nicoletta ; Colombo, Delia ; Peruzzi, Elena ; Pigatto, Paolo. / Cyclosporine in chronic idiopathic urticaria : A double-blind, randomized, placebo-controlled trial. In: Journal of the American Academy of Dermatology. 2006 ; Vol. 55, No. 4. pp. 705-709.
@article{704a7a83544f4666b340f0164e63b23e,
title = "Cyclosporine in chronic idiopathic urticaria: A double-blind, randomized, placebo-controlled trial",
abstract = "Background: Treatment of severe recalcitrant chronic idiopathic urticaria (CIU) is difficult. Objective: To assess the efficacy and safety of oral cyclosporin A (CsA) in CIU. Methods: The response to CsA was evaluated in 99 CIU patients with a double-blind, randomized, three-armed study: 16-week CsA, 8-week CsA +8-week placebo, and 16-week placebo. All patients received cetirizine throughout the study period and were followed-up after 8 weeks. Results: Fewer therapeutic failures occurred with 16-week CsA (n = 3) than with placebo (n = 11) and 8-week CsA (n = 8). After 8 and 16 weeks, symptom scores significantly improved in both CsA groups over with placebo. Two patients discontinued because of hypertension. Limitations: During the study period, CsA was not administered at a constant dose; from day 28 the daily dose was 3 mg/kg, which is likely to be less effective and better tolerated than higher dosages. Conclusion: CsA in addition to background therapy with cetirizine may be useful in the treatment of CIU.",
author = "Vena, {Gino A.} and Nicoletta Cassano and Delia Colombo and Elena Peruzzi and Paolo Pigatto",
year = "2006",
month = "10",
doi = "10.1016/j.jaad.2006.04.078",
language = "English",
volume = "55",
pages = "705--709",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Cyclosporine in chronic idiopathic urticaria

T2 - A double-blind, randomized, placebo-controlled trial

AU - Vena, Gino A.

AU - Cassano, Nicoletta

AU - Colombo, Delia

AU - Peruzzi, Elena

AU - Pigatto, Paolo

PY - 2006/10

Y1 - 2006/10

N2 - Background: Treatment of severe recalcitrant chronic idiopathic urticaria (CIU) is difficult. Objective: To assess the efficacy and safety of oral cyclosporin A (CsA) in CIU. Methods: The response to CsA was evaluated in 99 CIU patients with a double-blind, randomized, three-armed study: 16-week CsA, 8-week CsA +8-week placebo, and 16-week placebo. All patients received cetirizine throughout the study period and were followed-up after 8 weeks. Results: Fewer therapeutic failures occurred with 16-week CsA (n = 3) than with placebo (n = 11) and 8-week CsA (n = 8). After 8 and 16 weeks, symptom scores significantly improved in both CsA groups over with placebo. Two patients discontinued because of hypertension. Limitations: During the study period, CsA was not administered at a constant dose; from day 28 the daily dose was 3 mg/kg, which is likely to be less effective and better tolerated than higher dosages. Conclusion: CsA in addition to background therapy with cetirizine may be useful in the treatment of CIU.

AB - Background: Treatment of severe recalcitrant chronic idiopathic urticaria (CIU) is difficult. Objective: To assess the efficacy and safety of oral cyclosporin A (CsA) in CIU. Methods: The response to CsA was evaluated in 99 CIU patients with a double-blind, randomized, three-armed study: 16-week CsA, 8-week CsA +8-week placebo, and 16-week placebo. All patients received cetirizine throughout the study period and were followed-up after 8 weeks. Results: Fewer therapeutic failures occurred with 16-week CsA (n = 3) than with placebo (n = 11) and 8-week CsA (n = 8). After 8 and 16 weeks, symptom scores significantly improved in both CsA groups over with placebo. Two patients discontinued because of hypertension. Limitations: During the study period, CsA was not administered at a constant dose; from day 28 the daily dose was 3 mg/kg, which is likely to be less effective and better tolerated than higher dosages. Conclusion: CsA in addition to background therapy with cetirizine may be useful in the treatment of CIU.

UR - http://www.scopus.com/inward/record.url?scp=33749021931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749021931&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2006.04.078

DO - 10.1016/j.jaad.2006.04.078

M3 - Article

C2 - 17010756

AN - SCOPUS:33749021931

VL - 55

SP - 705

EP - 709

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 4

ER -